The founding of ALX Oncology was based upon technology invented at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1
ALX Oncology is an independent, private biotechnology company. Since May 2015, we have raised a total of $176 million in funding.
Senior Director, Finance and Controller
Chief Business Officer
Vice President, Operations
Senior Director, Clinical Science
Abraham Fong, M.D., Ph.D.
Senior Director, Clinical Development
Scientific Associate I
Chief Financial Officer
Director of Strategy and Corporate Development
Director, Corporate Development
Vice President, Finance and Chief Accounting Officer
President and Chief Executive Officer
Chief Medical Officer
Katherine Ruffner, M.D.
Vice President, Clinical Development
Vice President, Protein Science
Vice President, Chemistry, Manufacturing, and Controls
Chief Scientific Officer
Vice President, Regulatory Affairs
Acting General Counsel
- Kipp Weiskopf, et al. Science 341, 88 (2013);
Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23722425